Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4491737 | 0.69 | USP2 (0.51) | HPGDUSP2SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5359033 | 0.67 | HPGD (0.40) | HPGDUSP2SMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL5357446 | 0.66 | ADORA2A (0.38) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5361269 | 0.65 | NUDT1 (0.41) | — | |
| SCHEMBL10238819 | 0.62 | ALDH1A1 (0.71) | HPGDUSP2SMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL20037056 | 0.61 | GAA (0.60) | SMN1; SMN2ALDH1A1HSD17B10MAPTLMNA | |
| SCHEMBL22580172 | 0.60 | ALDH1A1 (0.52) | HPGDUSP2SMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL30753604 | 0.60 | ALDH1A1 (0.52) | HPGDUSP2SMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL14435485 | 0.60 | SMN1; SMN2 (0.45) | HPGDUSP2SMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL654364 | 0.59 | HPGD (0.40) | HPGDSMN1; SMN2ALDH1A1HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285543-B2 | Purine inhibitors of fructose-1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20050277619-A1 | Novel purine inhibitors of fructose-1,6-bisphosphatase | DANG QUN | 2005-12-15 | — | — | US | disclosed |
| US-6967193-B1 | Purine inhibitors of fructose-1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-6284748-B1 | ANTIDIABETIC AGENT | METABASIS THERAPEUTICS, INC. | 2001-09-04 | — | — | US | disclosed |
| WO-1998039344-A9 | NOVEL PURINE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | — | 1999-01-21 | — | — | WO | disclosed |
| WO-1998039344-A1 | NOVEL PURINE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277619-A1 | Novel purine inhibitors of fructose-1,6-bisphosphatase | FBP1, PNP, PPA1 | HPGD 698/4885USP2 4292/4885SMN1; SMN2 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.